HALOZYME THERAPEUTICS INC
NASDAQ: HALO (Halozyme Therapeutics, Inc.)
Kemas kini terakhir: 3 jam lalu107.20
0.20 (0.19%)
| Penutupan Terdahulu | 107.00 |
| Jumlah Dagangan | 861,263 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.92 |
| Harga / Jualan (P/S) | 7.87 |
| Harga / Buku (P/B) | 84.75 |
| Julat 52 Minggu |
| Margin Keuntungan | 44.76% |
| Margin Operasi (TTM) | 53.44% |
| EPS Cair (TTM) | 3.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 35.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 53.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 318.67% |
| Nisbah Semasa (MRQ) | 8.39 |
| Aliran Tunai Operasi (OCF TTM) | 503.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 402.43 M |
| Pulangan Atas Aset (ROA TTM) | 18.50% |
| Pulangan Atas Ekuiti (ROE TTM) | 147.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Halozyme Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.90 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.11% |
| % Dimiliki oleh Institusi | 101.53% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bank Of America Corp /De/ | 30 Jun 2026 | 2,740,561 |
| William Blair Investment Management, Llc | 30 Jun 2026 | 2,511,050 |
| Snyder Capital Management L P | 30 Jun 2026 | 2,396,101 |
| Los Angeles Capital Management Llc | 30 Jun 2026 | 1,938,035 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| APPELHANS DANNIELLE | 107.72 | - | 1,161 | 125,063 |
| Jumlah Keseluruhan Kuantiti Bersih | 1,161 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 125,063 | |||
| Purata Pembelian Keseluruhan ($) | 107.72 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| APPELHANS DANNIELLE | Pengarah | 01 Sep 2026 | Diperolehi (+) | 1,161 | 107.72 | 125,063 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |